Viking Therapeutics commences Phase I trial of VK3019

​Viking Therapeutics has commenced a Phase I clinical trial of VK3019, a DACRA, which is under development as a potential weight loss treatment option.

The post Viking Therapeutics commences Phase I trial of VK3019 appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

RQ Bio secures $115m to develop influenza antibody programme
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
Haisco and Nuvectis sign licensing deal for two drugs
Pfizer reports topline data from SigVie-002 study for NSCLC
CereVasc concludes patient enrolment in STRIDE trial of eShunt

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us